Annexon, Inc. Profile Avatar - Palmy Investing

Annexon, Inc.

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets disti…

Biotechnology
US, Brisbane [HQ]

Document Reader

Click To Read:

DEF 14-A Proxies

Not a single DEF 14-A proxy doc.

10-K Filings

Not a single 10-K doc.

10-Q Filings

Not a single 10-Q doc.

LDA 1/2 Filings [Lobbying]

Not a single LDA doc.

End of ANNX's Analysis
CIK: 1528115 CUSIP: 03589W102 ISIN: US03589W1027 LEI: - UEI: -
Secondary Listings
ANNX has no secondary listings inside our databases.